Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 64, Issue 7, 2008, Pages 683-690

  Orrell, Catherine ^a   Little, Francesca ^a   Smith, Peter ^a   Folb, Peter ^a   Taylor, Walter ^b   Olliaro, Piero ^b   Barnes, Karen I ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Amodiaquine; Artesunate; Healthy normal volunteers; Pharmacokinetics; Tolerability

Indexed keywords

AMODIAQUINE; ARTESUNATE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ;

ADULT; AFRICA; AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MONOTHERAPY; NEUTROPENIA; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TRANSAMINITIS;

ADULT; AMODIAQUINE; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE;

EID: 44449129845     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0452-8     Document Type: Article

References (24)

1. World Health Organisation (2006) WHO guidelines for the treatment of malaria. http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
2. World Health Organisation (2006) Facts on ACTs (artemisinin-based combinations). http://www.rollbackmalaria.org/cmc_upload/0/000/015/364/ RBMInfosheet_9.pdf
3. Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR et al (1986) Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1(8478):411-414
4. Larrey D, Castot A, Pessayre D, Merigot P, Machayekhy JP, Feldmann G et al (1986) Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 104(6):801-803
5. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J (1986) Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 292(6522):721-723
6. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M et al (2002) Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359(9315):1365-1372
7. Orrell C, Taylor WR, Olliaro P (2001) Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. Trans R Soc Trop Med Hyg 95(5):517-518
8. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal P, Charlebois E et al (2007) Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Inf Dis 44:889-891
9. Winstanley PA, Edwards G, Orme M, Breckinridge AM (1987) The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 23:1-7
10. Krishna S, White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinetics 30(4):263-299
11. Benakis A, Paris M, Loutan L, Plessas CT, Plessas ST (1997) Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am J Trop Med Hyg 56:17-23
12. Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N (2000) Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 44(4):972-977
13. Edwards IR, Biriell C (1994) Harmonization in pharmacovigilance. Drug Safety 10(2):93-102
14. NIH (1999) Common toxicity criteria, version 2.0. http://ctep.cancer.gov/ forms/CTCv20_4-30-992.pdf
15. Batty KT, Davis TME, Thus LTA, Binh TQ, Anh TK, Ilett KF (1996) Selective high-performance liquid chromatographic determination of artesunate and alpha and beta-dihydroartemisinin in patients with falciparum malaria. J Chromatogr 677:345-350
16. Karbwang J, Na-Bangchang K, Thanavibul A, Molunto P (1998) Plasma concentrations of artemether and its major plasma metabolite, dihydroartemsinin, following a 5-day regimen of oral artemether, in patients with uncomplicated falciparum malaria. Ann Trop Med Parasitol 92(1):31-36
17. Silamut K, Newton PN, Teja-Isavadharm P, Suputtamongkol Y, Siriyanonda D, Rasameesoraj M, Pukrittayakamee S, White NJ (2003) Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. Antimicrob Agents Chemother 47(12):3795-3798
18. Hietala SF, Bhattarai A, Msellem M, Roshammar D, Ali AS, Stromberg J, Hombhanje FW, Kaneko A, Bjorkman A, Ashton M (2007) Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn 34(5):669-686
19. Teja-Isavadharm P, Watt G, Eamsila C, Jongsakul K, Li Q, Keeratithakul G et al (2001) Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 65(6):717-721
20. Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G et al (1990) The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol 29(6):695-701
21. Hombhanje FW, Hwaihwanje I, Tsukahara T, Saruwatari J, Nakagawa M, Osawa H et al (2005) The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol 59(3):298-301
22. White NJ (2002) The assessment of antimalarial drug efficacy. Trends Parasitol 18(10):458-464
23. Barnes KI, Watkins WM, White NJ (2008) Antimalarial dosing regimens and drug resistance. Trends Parasitol 24(3):127-134
24. Winstanley PA, Edwards G, Orme ML, Breckenridge AM (1987) Effect of dose size on amodiaquine pharmacokinetics after oral administration. Eur J Clin Pharmacol 33(3):331-333